The Myeloproliferative Neoplasm Research Consortium (MPN-RC) is an inter-active group of laboratory and clinical scientists from 11 institutions throughout North America who will continue to work in a coordinated fashion to develop therapeutic strategies intended to improve the survival of patients with the myeloproliferative neoplasm (MPN), myelofibrosis (MF). The MPNs which also include polycythemia vera (PV), and essential thrombocythemia (ET) are clonal hematological malignancies which affect at least 300,000 individuals in the United States and are recognized as rare diseases by the National Cancer Institute (NCI). The Consortium has received continuous NCI funding since 2006 to elucidate the pathogenetic mechanisms underlying MPNs and address the unmet clinical needs of MPN patients. In the present application, we have chosen to focus our efforts on MF since it is the MPN with the shortest survival and at present allogeneic hematopoietic stem cell transplantation is the only approach which substantially alters its natural history. During the last decade, MF patients have received enormous clinical benefit from the widespread use of the JAK1/2 inhibitor, ruxolitinib, which is the first drug approved for the treatment of MF patients. Unfortunately, this drug (and others in the class) does not substantially halt disease progression and offers minimal improvement in survival. The limitations of this class of drugs can be attributed to an inability to eliminate MF hematopoietic stem cells (HSC) and/or disarm supportive microenvironments. To improve MF patient survival, we hypothesize that drugs capable of effectively depleting MF HSCs but sparing their normal counterparts be utilized. These drugs would act by directly targeting malignant HSCs and/or by correcting their tumor promoting micro-environments. Lessons learned from these studies will be useful to scientists and clinicians studying a large number of other cancers. The overall goal of the MPN-RC is to employ the complementary skills and efforts of its scientifically diverse membership to generate the scientific foundation for novel therapeutic strategies which will be evaluated in well-constructed, independent, investigator-initiated early phase clinical trials. To achieve these goals the following Specific Aims will be pursued:
Specific Aim 1 : To develop the scientific rationale for the use of therapeutic agents which deplete or eliminate MF stem cells by directly targeting malignant MPN stem cells.
Specific Aim 2 : To target aberrant inflammatory signaling and dysregulated gene expression in MF cells and in the microenvironment which drives disease progression.
Specific Aim 3 : To rationally design and rapidly execute preclinical studies and investigator-initiated phase I/II clinical trials with novel agents, including biomarker based studies embedded within our clinical trial platform to document efficacy of novel MF therapies.
Specific Aim 4 : Actively and dynamically maintain the scientific research and clinical research infrastructure needed to support and coordinate the performance of all laboratory investigations and clinical trials planned by the MPN-RC.
The Myeloproliferative Neoplasm Research Consortium (MPN-RC) is an inter-active group of laboratory and clinical scientists from 11 institutions who will work in a coordinated fashion to develop and evaluate therapeutic strategies that will improve the survival of patients with myelofibrosis (MF). We hypothesize that drugs which act by directly targeting malignant hematopoietic stem cells and/or by correcting their tumor promoting micro-environments can be used to deplete the numbers of cancer stem cells. The overall goal of the MPN-RC is to employ the complementary skills and efforts of its scientifically diverse membership to generate the scientific foundation for novel therapeutic strategies which will be evaluated in rigorous, well- constructed independent investigator-initiated clinical trials.
|Wang, Xiaoli; Hu, Cing Siang; Petersen, Bruce et al. (2018) Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv 2:2378-2388|
|Zimran, Eran; Tripodi, Joseph; Rampal, Raajit et al. (2018) Genomic characterization of spleens in patients with myelofibrosis. Haematologica 103:e446-e449|
|Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:785-787|
|Qiu, Jiajing; Salama, Mohamed E; Hu, Cing Siang et al. (2018) The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. Blood Adv 2:1130-1145|
|Pronier, Elodie; Cifani, Paolo; Merlinsky, Tiffany R et al. (2018) Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight 3:|
|Migliaccio, Anna Rita (2018) A vicious interplay between genetic and environmental insults in the etiology of blood cancers. Exp Hematol 59:9-13|
|Gupta, Vikas; Kosiorek, Heidi E; Mead, Adam et al. (2018) Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant :|
|Gnanapragasam, Merlin Nithya; Crispino, John D; Ali, Abdullah M et al. (2018) Survey and evaluation of mutations in the human KLF1 transcription unit. Sci Rep 8:6587|
|Migliaccio, Anna Rita; Varricchio, Lilian (2018) Concise Review: Advanced Cell Culture Models for Diamond Blackfan Anemia and Other Erythroid Disorders. Stem Cells 36:172-179|
|Ling, Te; Crispino, John D; Zingariello, Maria et al. (2018) GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy. Expert Rev Hematol 11:169-184|
Showing the most recent 10 out of 195 publications